Immunome Inc. (IMNM)
D
Pipeline Grade
Financial Position (from SEC Filings)
$582.9M
Cash & Equivalents
$58.6M
Quarterly Burn Rate
30 mo
Est. Cash Runway
$2,644M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (5)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT04871282 | A Study of AL102 in Patients With Progressing Desmoid Tumors | PHASE3 | Active Not Recruiting | 198 |
| NCT06823167 | A Phase 1 Study of IM-1021 in Participants With Advanced Cancer | PHASE1 | Recruiting | 117 |
| NCT07578571 | A Phase 1 Study of IM-1617 in Participants With Advanced Cancer | PHASE1 | Recruiting | 175 |
| NCT07610005 | A Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy Participants | PHASE1 | Recruiting | 20 |
| NCT07505771 | A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer | PHASE1 | Recruiting | 105 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.